Expert’s Pick of the Week | 30th April, 2018 | Buy Hold Sell

Experts’ Advice of the Week | 30th April, 2018

BUY | HOLD | SELL     What to do?

What can you Buy or Sell?

Top 7 stocks from different brokerage houses with their comments.

 

Crompton Consumer:

Research House: JP Morgan
Advice: Overweight
Market Price Rs.: 229
1 Year Target Price Rs.: 300
Potential Upside: 31%

Retain Overweight.
Risk-reward ratio for Crompton Consumer is attractive at current levels. The market share slippage seen in the pumps business last quarter is a temporary blip.

Gujarat Gas:

Research House: Elara Capital
Advice: Buy
Market Price Rs.: 856
1 Year Target Price Rs.: 1115
Potential Upside: 30%

Reiterate Buy.
Gujarat Gas will benefit from higher furnace oil prices. Upgrading of domestic refineries will potentially lower annualized furnace oil supply by 20%, pushing up domestic prices.

ICICI Prudential Life:

Research House: Citi Research
Advice: Buy
Market Price Rs.: 431
1 Year Target Price Rs.: 525
Potential Upside: 22%

Upgrade to Buy.
ICICI Prudential Life has delivered strong growth in new business premium and has consistently ranked number one in terms of individual premium market share.

See also: Rain Industries| CMP INR 366.90 | Target INR 800 | Double The Money Target

Yes Bank:

Research House: Macquarie Cap
Advice: Outperform
Market Price Rs.: 352
1 Year Target Price Rs.: 425
Potential Upside: 21%

Maintain Outperform.
It is the only corporate lender without any non-performing loan resolution or revised stressed asset framework baggage, freeing it to capture market share from other banks.

Shriram Transport Finance:

Research House: Edelweiss Fin.
Advice: Buy
Market Price Rs.: 1639
1 Year Target Price Rs.: 1951
Potential Upside: 19%

Initiate Buy.
Commercial vehicle finance firms are expected to grow fast due to CV sales led by improving road connectivity and rural dynamics, and rising demand for higher tonnage trucks.

Rallis India:

Research House: Ambit Capital
Advice: Sell
Market Price Rs.: 234
1 Year Target Price Rs.: 205
Potential Upside: -13%

Reiterate Sell.
No reason to hold the stock due to expensive valuation 20 times. Its expected earnings per share in 2018-19 and no growth in EBITDA for the past four years.

See also: ALEMBIC PHARMACEUTICALS LIMITED – FUNDAMENTAL ANALYSIS

Wipro:

Research House: IIFL
Advice: Reduce
Market Price Rs.: 281
1 Year Target Price Rs.: 260
Potential Upside: -8%

Maintain Reduce.
Its 1.1% Q-o-Q revenue growth in constant currency, is at the lower end of its guidance range of 1-3%. Wipro is justifiably trading at a discounts to peers.

 

You might like this: What is Value Investing? Detailed study

Our Blog website: http://multibaggerspoint.com/

Follow us on Facebook: https://www.facebook.com/multibaggerspoint1

Follow us on YouTube: https://www.youtube.com/multibaggerspoint


Disclaimer:

My descriptions, videos, presentations are only for educational and information purposes and under no circumstances should be used for making investment decisions. I cannot guarantee the accuracy of any information provided.
The stocks picks are based on my own research and personal views and sometimes are from newspapers, tv channel program, magazines, etc. No part of compensation is or will be directly or indirectly related to the views and recommendations of this research. I have not served as an officer director or employee of the company and have not been engaged in the market – making the activity of the company covered in the research report. Consult qualified financial advisor before making any investment decision.

Leave a Reply

Your email address will not be published. Required fields are marked *